Dermatitis News and Research

Latest Dermatitis News and Research

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement”) with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.

1 Sep 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.

25 May 2009

Researchers look at eczema asthma link

Many young children who get a severe skin rash develop asthma months or years later. Doctors call the progression from eczema, or atopic dermatitis, to breathing problems the atopic march. In the May 2009 issue of PLoS Biology, scientists at Washington University School of Medicine in St. Louis report another step taken towards understanding the process of atopic march.

18 May 2009

Household bleach has a surprising new role: an effective treatment for kids' chronic eczema

Researchers from the Northwestern University Feinberg School of Medicine have discovered powerful relief in the form of diluted beach baths. It's a cheap, simple and safe treatment that drastically improves the rash as well as reduces flare-ups of eczema, which affects 17 percent of school-age children.

27 Apr 2009

Review of homeopathic medicines in easing cancer therapy symptoms

Drugs and radiotherapy given for cancer can cause unpleasant side effects such as nausea and vomiting, mouth sores, dermatitis, and menopausal symptoms.

14 Apr 2009

Serentis begins trial with first-in-class SRD441 for eczema

Serentis, a privately owned biopharmaceutical company, announced that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.

9 Apr 2009

Research could lead to new non-antibiotic drugs to counter hospital infections

Lack of an adequate amount of the mineral phosphate can turn a common bacterium into a killer, according to research to be published in the April 14, 2009, issue of the Proceedings of the National Academies of Science.

9 Apr 2009

Homeopathy in dogs pilot indicates need for larger clinical trial

Results from a small, rigorously designed, research study at the University of Bristol's Department of Clinical Veterinary Science have pointed the way towards a larger clinical trial of homeopathy for the treatment of atopic dermatitis in dogs.

7 Apr 2009

Discovery of gene variant associated with increased risk of atopic dermatitis

Scientists of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and Charité - University Medical School, Berlin, Germany, in collaboration with researchers from the Klinikum rechts der Isar of Technical University Munich and Christian Albrecht University, Kiel, have identified a gene variant on chromosome 11 that is associated with an increased risk of atopic dermatitis.

6 Apr 2009

Discovery may lead to immunosuppressant drugs that have fewer adverse side effects

Immunosuppressive treatment is necessary to prevent rejection of an organ after transplant and has great potential for treating chronic inflammatory diseases.

12 Mar 2009

BioCis Pharma starts trial of novel topical drug for dermatology

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure emulsion cream, the company's novel topical drug for dermatology.

12 Mar 2009

Tissue-cultured smallpox vaccine shows promise

Administration of a tissue-cultured smallpox vaccine showed signs of an effective vaccine response with no serious adverse events, according to a study in the March 11 issue of JAMA, the Journal of the American Medical Association.

11 Mar 2009

Powder-free latex gloves decrease allergy risk in hospitals

Using powder-free latex gloves rather than those with cornstarch powder greatly reduced the number of workers' compensation claims related to latex-related illness, a recent Geisinger study found.

8 Mar 2009

Emerging therapies could ease symptoms of Atopic dermatitis

Atopic dermatitis, the common, chronic, inflammatory skin disease marked by red, itchy rashes, has been increasing in prevalence over the past two decades and affects a disproportionate number of children.

5 Mar 2009

Pre-emptive treatment helped curtail skin toxicity with Panitumumab

With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

19 Jan 2009

Dermatitis News and Research

Latest Dermatitis News and Research

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers look at eczema asthma link

Household bleach has a surprising new role: an effective treatment for kids' chronic eczema

Review of homeopathic medicines in easing cancer therapy symptoms

Serentis begins trial with first-in-class SRD441 for eczema

Research could lead to new non-antibiotic drugs to counter hospital infections

Homeopathy in dogs pilot indicates need for larger clinical trial

Discovery of gene variant associated with increased risk of atopic dermatitis

Discovery may lead to immunosuppressant drugs that have fewer adverse side effects

BioCis Pharma starts trial of novel topical drug for dermatology

Tissue-cultured smallpox vaccine shows promise

Powder-free latex gloves decrease allergy risk in hospitals

Emerging therapies could ease symptoms of Atopic dermatitis

Pre-emptive treatment helped curtail skin toxicity with Panitumumab

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Dermatitis News and Research

Latest Dermatitis News and Research

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in